Clinical study demonstrates bevacizumab reduces epistaxis-related surgical ablations in hereditary hemorrhagic telangiectasia, highlighting the need for standardized maintenance dosing.
KEY POINTS: Bevacizumab reduced epistaxis-related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standardization.
No takes yet. Share an insight, caveat, or question.
Barefoot et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: